信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

VOLUNTARY ANNOUNCEMENT INCLUSION OF SEVEN INNOVATIVE DRUGS INCLUDING TYVYT® NEW INDICATION AND SYCUME® IN CHINA'S NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Innovent Biologics, Inc. (the "**Company**" or "**Innovent**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List of China ("**NRDL**"). This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions of SYCUME® (teprotumumab N01 injection, a recombinant anti-IGF-1R antibody), Limertinib (EGFR TKI), Dupert® (fulzerasib, KRAS G12C inhibitor), DOVBLERON® (taletrectinib, ROS1 inhibitor), Retsevmo® (selpercatinib, RET inhibitor), and Jaypirca® (pirtobrutinib, BTK inhibitor). The updated NRDL will be officially effective from January 1, 2026.

The Company is pleased with the NRDL inclusion of our seven innovative therapies this year. These therapies cover key disease areas that pose substantial public health challenges in China – particularly oncology (including lung, liver, gastric, esophageal, gynecological cancers, and hematological malignancies) as well as cardiovascular and metabolic ("**CVM**") diseases. Their inclusion will help broaden patients' access to and enhance their affordability of these medications, ultimately benefiting more individuals and families across the country. As a company with the mission of "empowering patients worldwide with affordable, high-quality biopharmaceuticals", Innovent continues to invest in pioneering treatments across oncology, CVM, autoimmune and ophthalmology – areas of significant social need. We remain committed to our patient-centered approach, leveraging our innovation and product capabilities to further improve drug affordability and accessibility, so that high-quality medicines can reach and benefit more patients and their families as soon as possible. The Company is proud to contribute to better care for patients.

TYVYT® (sintilimab injection)

TYVYT® (sintilimab injection) is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company. In China, sintilimab has been approved for eight indications and two more new drug applications (NDA) are under review by the China National Medical Products Administration (NMPA), including squamous non-small cell lung cancer ("**NSCLC**"), non-squamous NSCLC liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin's lymphoma.

In the updated NRDL, the eighth indication of TYVYT® (sintilimab injection) is newly included, in combination with fruquintinib for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient (pMMR) tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation. This new indication addresses a critical gap in treatments available for advanced endometrial cancer patients with limited responses to traditional therapies.

SYCUME® (teprotumumab N01 injection)

SYCUME® (teprotumumab N01 injection) is a recombinant anti-IGF-1R antibody developed by Innovent. SYCUME® blocks the activation of IGF-1R signaling pathway, consequently improving clinical manifestations such as proptosis, inflammation and diplopia, thus enhancing quality of life in patients with thyroid eye disease ("**TED**").

In the updated NRDL, SYCUME® (teprotumumab N01 injection) is newly listed for moderate-to-severe TED. SYCUME® (teprotumumab N01 injection) is China's first approved IGF-1R antibody drug, and this groundbreaking non-invasive therapy redefines the standard of care and serves the unmet needs for TED over the past 70 years in China. The NRDL inclusion will bring this world-class novel treatment option to Chinese patients with TED and significantly improve patient access to and affordability of medicines.

Limertinib

Limertinib is a third-generation EGFR TKI in collaboration with ASK Pharm, and Innovent holds exclusive commercialization rights in Mainland China.

In the updated NRDL, limertinib is newly listed for: 1) the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated NSCLC, who have previously experienced disease progression during or after treatment with EGFR TKI; and 2) the first-line treatment of adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations. Limertinib incorporates a unique naphthylamine group structure, which endows it with enhanced lipophilicity. This property ensures effective drug penetration across the blood-brain barrier (BBB), thereby significantly reducing the risk of disease progression – specifically, the risk of disease progression in patients with brain metastases and the risk of intracranial disease progression. The NRDL inclusion of limertinib will provide a more effective treatment option for NSCLC patients with EGFR mutations.

Dupert® (fulzerasib)

Dupert® (fulzerasib) is a novel KRAS G12C inhibitor in collaboration with GenFleet Therapeutics, and Innovent holds exclusive development and commercialization rights in Greater China.

In the updated NRDL, Dupert® (fulzerasib) is newly listed for the treatment of advanced NSCLC adult patients harboring KRAS G12C mutation who have received at least one systemic therapy. The NRDL inclusion of Dupert® (fulzerasib) will provide a novel targeted therapy benefiting NSCLC patients harboring KRAS G12C mutation.

DOVBLERON® (taletrectinib)

DOVBLERON® (taletrectinib) is a novel next-generation ROS1 TKI in collaboration with Nuvation Bio China, a Nuvation Bio (NYSE: NUVB) Company, and Innovent holds exclusive commercialization rights in Greater China.

In the updated NRDL, DOVBLERON® (taletrectinib) is newly listed for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. The NRDL inclusion of DOVBLERON® (taletrectinib) will provide a potentially best-in-class therapy benefiting patients with locally advanced ROS1-positive NSCLC.

Retsevmo® (selpercatinib)

Retsevmo® (selpercatinib) is a selective and potent RET kinase inhibitor developed by Eli Lilly and Company and commercialized in Mainland China solely by Innovent.

In the updated NRDL, Retsevmo® (selpercatinib) is newly listed for the treatment of: 1) adult patients with locally advanced or metastatic NSCLC with a RET gene fusion, 2) adult and pediatric patients 12 years of age and older with advanced or metastatic MTC with a RET mutation who require systemic therapy, and 3) adult and pediatric patients 12 years of age and older with advanced or metastatic TC with a RET gene fusion who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). Retsevmo® (selpercatinib) is the first RET inhibitor approved globally and its NRDL inclusion will bring an innovative therapy for NSCLC and thyroid cancer patients with a RET alteration.

Jaypirca® (pirtobrutinib)

Jaypirca® (pirtobrutinib) is a non-covalent (reversible) Bruton's tyrosine kinase ("**BTK**") inhibitor developed by Eli Lilly and Company and commercialized in Mainland China solely by Innovent. Jaypirca® (pirtobrutinib) is first and only non-covalent (reversible) BTK inhibitor approved in the world.

In the updated NRDL, Jaypirca® is newly listed for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least two types of systemic therapy, including a BTK inhibitor. Its NRDL inclusion will benefit heavily-treated MCL patients that previously received the treatment of a BTK inhibitor, addressing their unmet needs and further enhancing Jaypirca®'s affordability for those patients.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China,
December 7, 2025

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and Executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as Executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as Independent Non-executive Directors.